{"news_desk": "Business", "print_page": "1", "subsection_name": null, "section_name": "Business Day", "byline": {"original": "By KATIE THOMAS and MATTHEW GOLDSTEIN", "person": [{"firstname": "Katie", "rank": 1, "lastname": "THOMAS", "organization": "", "role": "reported"}, {"firstname": "Matthew", "rank": 2, "lastname": "GOLDSTEIN", "organization": "", "role": "reported"}]}, "abstract": "Federal prosecutors charge Philidor Rx Services chief exec Andrew Davenport and Valeant Pharmaceuticals International exec Gary Tanner with multiple counts of fraud and conspiracy; allege two made secret pact to enrich themselves through promotion of Philidor through Valeant via bribes and kickbacks.", "type_of_material": "News", "word_count": "1310", "keywords": [{"rank": "1", "value": "Valeant Pharmaceuticals International Inc", "is_major": "Y", "name": "organizations"}, {"rank": "2", "value": "Philidor Rx Services LLC", "is_major": "Y", "name": "organizations"}, {"rank": "3", "value": "Bribery and Kickbacks", "is_major": "Y", "name": "subject"}, {"rank": "4", "value": "Tanner, Gary", "is_major": "Y", "name": "persons"}, {"rank": "5", "value": "Davenport, Andrew", "is_major": "Y", "name": "persons"}], "lead_paragraph": "Gary Tanner, the former Valeant executive, entered into a secret relationship with Philidor\u2019s chief executive, Andrew Davenport, federal authorities said.", "pub_date": "2016-11-17T15:36:54Z", "document_type": "article", "source": "The New York Times", "snippet": "Gary Tanner, the former Valeant executive, entered into a secret relationship with Philidor\u2019s chief executive, Andrew Davenport, federal authorities said....", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wide": "images/2016/11/18/business/18VALEANTsub/18VALEANTsub-thumbWide-v2.jpg", "wideheight": "126"}, "type": "image", "width": 190, "url": "images/2016/11/18/business/18VALEANTsub/18VALEANTsub-thumbWide-v2.jpg"}, {"height": 431, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "431", "xlarge": "images/2016/11/18/business/18VALEANTsub/18VALEANTsub-articleLarge-v2.jpg"}, "type": "image", "width": 600, "url": "images/2016/11/18/business/18VALEANTsub/18VALEANTsub-articleLarge-v2.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/11/18/business/18VALEANTsub/18VALEANTsub-thumbStandard-v2.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "url": "images/2016/11/18/business/18VALEANTsub/18VALEANTsub-thumbStandard-v2.jpg"}], "web_url": "http://www.nytimes.com/2016/11/18/business/valeant-philidor-fraud-kickback-scheme.html", "slideshow_credits": null, "blog": [], "_id": "582dce9d7c459f6a5fcce8cc", "headline": {"main": "Former Drug Industry Executives Charged in Kickback Scheme", "print_headline": "Charges in Drug Industry Kickbacks Case"}}